Cat. No. | Product name | CAS No. |
DC71559 |
IZTZ-1
Featured
IZTZ-1, an imidazole-benzothiazole conjugate, is a c-MYC G4 ligand. IZTZ-1 is able to downregulate the c-MYC expression by stabilizing c-MYC G4. IZTZ-1 induces cell cycle arrest, apoptosis, thereby inhibiting cell proliferation in B16 cells. IZTZ-1 shows antitumor activity, and can be used for melanoma research. |
2636771-45-2 |
DC71577 |
Haloperidol lactate
Featured
Haloperidol lactate is a potent antipsychotic agent. Haloperidol lactate can be used in acute and chronic schizophrenia and gilles de la tourette's syndrome. Haloperidol lactate has the potential for the research of psychotic disorders. |
53515-91-6 |
DC60208 | NSC 31153 Featured | 6325-94-6 |
DC60209 | NSC 31152 Featured | 24138-83-8 |
DC80035 |
WAY-647802
Featured
WAY-647802 is a CDK inhibitor. |
852225-20-8 |
DC80036 |
ZINC36395841(compound 25)
Featured
ZINC36395841 is a small-molecule binder of the m6A-reader domain of YTHDC1. |
1181501-16-5 |
DC80040 |
MS8511
Featured
MS8511 is a highly potent, selective, and cell-active covalent inhibitor of G9a (Kd=44 nM) and GLP (Kd=46 nM). MS8511 could be a useful chemical tool for investigating the physiological and pathophysiological functions of G9a and GLP. |
|
DC60211 |
TCL053
Featured
TCL053 is an ionizable amino lipid.1 It has been used in the generation of lipid nanoparticles (LNPs) and has a pKa value of 6.8. LNPs containing TCL053 and encapsulating mRNA encoding the Cas9 nuclease, in combination with LNPs containing TCL053 and encapsulating single-guide RNA (sgRNA) targeting the Rosa26 locus, have been used to induce CRISPR-mediated gene editing in the mouse gastrocnemius muscle.TCL053 is an ionizable lipid that has received FDA approval for preparing mRNA vaccines. It is a three-tailed ionizable lipid to overcome the disadvantage of nonrepeatable administration of AAV vectors. In addition, combined with limb perfusion administration, TCL053 iLNPs could transiently deliver CRISPR-Cas9 mRNA and sgRNA to multiple muscle tissues, reducing immunogenicity and increasing the safety of iLNPs. It is great progress for treating Duchenne muscular dystrophy and other diseases that require multiple doses. |
2361162-70-9 |
DC60212 |
NT1-O14B
Featured
NT1-O14B is a tryptamine-containing cationic lipidoid.1 It has been used in combination with other lipids in the formation of lipid nanoparticles (LNPs). Intravenous administration of LNPs containing NT1-O14B and encapsulating antisense nucleotides against tau decreases tau brain levels in mice. |
2739805-64-0 |
DC60213 |
DOTMA
Featured
N-[1-(2,3-Dioleyloxy)propyl]-N,N,N-trimethylammonium (DOTMA) is a cationic lipid.It has been used as a component in liposomes that can be used to encapsulate siRNA, microRNAs, and oligonucleotides and for gene transfection in vitro. |
104162-48-3 |
DC60215 |
Lipid 29
Featured
Lipid 29 is an ionizable amino lipid (pKa = 6.91) that has been used in combination with other lipids in the formation of lipid nanoparticles (LNPs).Administration of human erythropoietin (EPO) mRNA in lipid 29-containing LNPs increases serum EPO levels in mice. |
2244716-55-8 |
DC60216 |
SB-747651A dihydrochloride
Featured
SB-747651A dihydrochloride is a potent MSK1 inhibitor; also inhibiting other AGC group kinases. |
1781882-72-1 |
DC60217 |
NBI-31772
Featured
NBI 31772 is a nonpeptide ligand that releases insulin-like growth factor-1 (IGF-1) from its binding protein (IGFBP; Kis = 1-24 nM for the six human subtypes of IGFBP).1,2 As the released IGF-1 is biologically active, NBI 31772 is used to assess the role of IGF-1 in cells and animals, including in neuron survival, skeletal muscle regeneration, and glucose homeostasis.3,4,5 |
374620-70-9 |
DC60218 |
Azidamfenicol
Featured
Azidamfenicol is a broad-spectrum chloramphenicol-like antibiotic that is active against Gram-negative and Gram-positive bacteria.1 It inhibits ribosomal peptidyltransferase (Ki = 22 µM).2 |
13838-08-9 |
DC60219 |
FHD-286
Featured
FHD286(FHD 286 ) is a BRG1/BRM ATPase inhibitor for the treatment of BAF-related disorders such as acute myeloid leukemia. |
2671128-05-3 |
DC60220 | GLUT inhibitor-1 Featured | 2421141-40-2 |
DC60221 |
MKC-1
Featured
MKC-1 is an orally bioavailable, small-molecule, bisindolylmaleimide cell cycle inhibitor with potential antineoplastic activity. MKC-1 and its metabolites inhibit tubulin polymerization, blocking the formation of the mitotic spindle, which may result in cell cycle arrest at the G2/M phase and apoptosis. |
125313-92-0 |
DC60222 |
RP 70676
Featured
RP 70676 is a potent and orally bioavailable inhibitor of ACAT. |
136609-26-2 |
DC60223 |
Viridicatol
Featured
Viridicatol is a fungal metabolite that has been found in various Penicillium species as well as Phoma with antimicrobial properties. |
14484-44-7 |
DC60224 | WAY-270599 Featured | 397281-20-8 |
DC60225 |
AOD-9604
Featured
AOD-9604 is a potential anti-obesity peptide based on human growth hormone. AOD9604 was originally developed after research on mice, but subsequent studies in human have shown no efficacy for the potential treatment of obesity. |
221231-10-3 |
DC60226 |
Beclamide
Featured
Beclamide is a drug that possesses anticonvulsant activity. It is no longer used. Beclamide is possibly metabolized to 3-chloropropanoic acid in vivo, which binds to the GHB receptor. It has been used as a sedative and as an anticonvulsant. It was studied in the 1950s for its anticonvulsant properties, as a treatment for generalised tonic-clonic seizures. It was not effective for absence seizures. Interest in the drug resumed in the 1990s for its psychiatric properties as an adjunct in the treatment of schizophrenia. While not classified as a DEA controlled substance in the United States, this product can only be sold STRICTLY to universities and research institutions. This product will not be sold to individuals or shipped to residential addresses. |
501-68-8 |